| INTRODUC TI ON
The mainstay of current haemophilia A treatment is coagulation factor VIII (FVIII) therapy, that is replacement of the absent endogenous FVIII by either plasma-derived (pdFVIII) or recombinant FVIII (rFVIII).
1 As underdosing of exogenous FVIII may result in insufficient FVIII cover and increase patients' bleeding risk, accurate assignment of the potency of FVIII concentrates is paramount. Likewise, accurate measurement of FVIII activity (FVIII:C) in plasma during treatment is essential for monitoring FVIII:C trough levels, assessment of FVIII pharmacokinetics and perioperative management of patients with haemophilia A.
2
FVIII:C in patients receiving FVIII replacement therapy can be measured by either one-stage or chromogenic substrate assays (OSAs and CSAs, respectively). The OSA is based on a modified activated partial thromboplastin time (aPTT) assay that is calibrated to a series of FVIII concentrations. 3 The CSA employs a two-stage design. In the first step, FVIII acts as a cofactor in the generation of activated coagulation factor X (FXa). The amount of FXa reflects the amount of FVIII in the sample and is determined by measuring the extent of FXa-mediated hydrolysis of a chromogenic substrate. 2, 4 While the number of commercially available CSAs is relatively small, a large number of different aPTT reagents are available. 5 This can lead to considerable variation in FVIII:C results, as OSA results are affected by the choice of phospholipid 6 and surface activator/ aPTT reagent, 7, 8 as well as by the von Willebrand factor content of the FVIII-deficient plasma. 9 These variations are typically observed with rFVIII concentrates 6, 9 or modified FVIII products, 7, 8 but not normally with pdFVIII concentrates. 6, 9 Inter-reagent variability is lower for CSAs, which represent the reference method of the European Pharmacopoeia for the potency assignment of products used for FVIII replacement therapy. 10 However, the majority of laboratories use OSAs for monitoring in the clinical setting.
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Discrepancies between FVIII:C determined by OSAs and CSAs have been observed for rFVIII concentrates, with CSA:OSA ratios typically between 1.1 and 1.3. 2 However, for ReFacto ® , a B-domaindeleted (BDD) rFVIII, OSA results were found to be 20%-50% lower than those obtained with the CSA. 6, 12 The use of a product-specific reference standard (reference laboratory standard, RLS) reduced this discrepancy and allowed for more accurate estimates using the OSA. 
22
The aim of this field study was to assess whether Nuwiq ® activity can be accurately measured with a variety of OSAs and CSAs used in routine laboratory practice. , a full-length rFVIII of hamster cell line origin, was chosen as a comparator as it was the most widely used rFVIII at the time the study was conceived, and it has been used as a comparator in field studies with other rFVIII products.
| Sample preparation
7,14,23-26
| Performance of assays
Participating laboratories were asked to determine FVIII:C on three separate days by means of whichever assay(s) they used routinely, following their standard procedures and using their in-house equipment. Results were reported as final calculated activities.
| Data analysis
All questionnaires and FVIII:C data were submitted to a central processing site that reviewed, edited and compiled the data. Compilation records were checked against the source files for 100% accuracy. In case of missing or implausible data, laboratories were contacted for clarification. For all analyses, except intralaboratory precision, one mean value per sample, assay and laboratory was calculated from the triplicate results provided. Intralaboratory precision was determined based on the three results for each sample.
Outlier detection was performed based on robust regression diagnostics with a cut-off equal to four times the mean.
| RE SULTS

| Participating laboratories
Of 59 laboratories invited, 50 agreed to participate in the study. One laboratory was subsequently excluded for logistical reasons and did not receive a study kit. Figure 1 shows the distribution of recovery values for the OSAs and CSAs. Results were comparable for Nuwiq ® and Advate ® at all concentrations. As observed for the mean values, median recovery decreased with increasing concentrations for both products.
| Methodologies used
| Activity results
| Absolute FVIII:C and mean recovery
| Distribution of recovery
| Inter-and intralaboratory precision
In accordance with the distribution patterns, interlaboratory CVs were high for low concentrations and decreased with increasing potency ( 
| Analyses by reagents
An analysis of FVIII:C recovery by aPTT reagent showed nearly twofold differences in mean recovery between reagents for the 1 IU/dL samples; however, standard deviations and ranges were large ( Figure 2 ). Comparable patterns were observed for Nuwiq Prest and the lowest recoveries with Pathromtin. Inter-reagent differences decreased with increasing concentrations and were almost non-existent for the 100 IU/dL samples. Similar results were obtained when the recoveries were analysed by activator (Table   S1 ). For both subgroup analyses, results for median recoveries were comparable to those for the means (data not shown).
| Analyses by instruments
FVIII:C recovery by instrument for the OSA is displayed in Figure S1 . (Table 3) .
| D ISCUSS I ON
This comparative international field study examined , which suggests that the variability is not related to differences in the products, but rather to methodological differences between the assays or to differences between individual laboratories. The greater variability in values at lower concentrations has also been observed in previous field studies with other rFVIII products, [23] [24] [25] [26] with measured values more than twice as high as expected for individual samples at the lowest concentrations assayed. 14, 23, 26 Of note, the lowest concentration used in this study, 1 IU/dL, is lower than that reported in previous studies, which generally ranged from 3 to 5 IU/dL 14,24-26 and was even 20 IU/dL in one case.
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For the OSA, high variability of assay results and overestimation of FVIII:C at low concentrations have been described previously. The CSA is generally assumed to be more sensitive at low concentrations. 27 However, results from previous field studies are inconsistent, 25, 26 and recent data from proficiency testing indicate that both
OSAs and CSAs show high variability at low concentrations. 28 It has been speculated that high variability at low target concentrations in the CSA may be due to the absence of very low concentration samples in calibration curves, 25 and in fact, according to the questionnaire data, the lowest concentration used for calibration was ≥2.5 IU/dL for almost one-third of CSAs in this study (data not shown). Independently of this, it is important to note that for samples 
TA B L E 2 Inter-and intralaboratory precision
Interlaboratory CV (%)
Mean intralaboratory CV (%) b
Interlaboratory CV (%)
Mean intralaboratory CV (%) F I G U R E 2 Target recovery (%) as determined by OSAs, analysed by aPTT reagent. Data are presented as mean ± SD (range). Only aPTT reagents used by at least five laboratories were included in the analysis. Results from one of the 51 assays were excluded due to an obvious calculation error affecting all reported FVIII:C values. aPTT, activated partial thromboplastin time; IU, international unit; OSA, one-stage assay; SD, standard deviation. Some values were excluded from the analysis because no exact FVIII:C values were provided; therefore, for the columns with footnotes, n is less than the n listed in the legend:
with a concentration as low as 1 IU/dL, large percentage differences correspond to very small differences in absolute FVIII:C values.
To decrease variation in FVIII:C, particularly when measuring high-purity FVIII concentrates, recommendations for the standardization of assays have been issued. 29 These include the use of FVIII-deficient plasma for predilution of samples and the use of 1% of albumin in all assay buffers. However, in our study using the as- Our study showed inter-reagent differences in FVIII:C of approximately twofold for both the OSA and the CSA at low concentrations. Differences of a similar magnitude between different aPTT reagents have been reported in a study using low concentrations of Afstyla ® . 32 Another study reported differences between aPTT reagents even at higher FVIII:C, with higher values observed for SynthASil vs Actin FS, 33 consistent with our results. Analyses by CSA reagents did not show any major inter-reagent differences but were exclusively based on samples with FVIII:C of >20 IU/dL, [33] [34] [35] in which marked differences are less likely to be found. In the present study, differences were less pronounced in the 30 and 100 IU/dL samples.
The influence of other methodological parameters has rarely been studied. A possible minor impact of the analyser on FVIII:C results has been reported in two small studies, 34, 35 with one of them showing a tendency towards higher recovery with ACL TOP compared with Sysmex for the OSA, 35 in line with our findings.
CSA:OSA ratios were comparable for both products and below or within the expected range of 1.1 to 1.3, 2 indicating that the deletion of the B-domain per se does not result in CSA-OSA discrepancies, which confirms observations from other field studies involving BDD rFVIII. 24, 26 In previous studies, usually only a low proportion of laboratories (one-third or below) provided results for CSAs. 7, 14, [23] [24] [25] [26] The present field study is the first such study with over 80% of laboratories routinely using CSAs and providing corresponding FVIII:C results.
This study has some limitations. First, although samples mimicked postinfusion samples from FVIII-deficient patients as closely as possible, it cannot be excluded that actual patient postinfusion samples may behave differently. 27 However, it was recently demonstrated for Advate ® that both types of samples yield comparable results in OSAs and CSAs. 35 Second, only one lot of each product and of FVIII-deficient plasma was used to prepare the samples, and as most laboratories performed the three assay runs within 2 weeks, the use of different reagent lots is unlikely. Third, the influence of some assay parameters was not analysed, because certain reagents were either not used in the study (eg FVIII-deficient plasma containing low levels of von Willebrand factor) or were used by one or two laboratories only, precluding reliable statistical analysis.
In conclusion, comparable FVIII:C results were obtained for Nuwiq ® and Advate ® across a range of concentrations and using a variety of OSA and CSA reagents. Therefore, both OSAs and CSAs F I G U R E 3 Target recovery (%) as determined by CSAs, analysed by assay kit. Data are presented as mean ± SD (range). Only kits used by at least five laboratories were included in the analysis. CSA, chromogenic assay; IU, international unit; SD, standard deviation. Some values were excluded from the analysis because no exact FVIII:C values were provided; therefore, for the columns with footnotes, n is less than the n listed in the legend: a n = 18; b n = 19; c n = 9; d n = 11
Hospital Abbreviations: CSA, chromogenic assay; IU, international unit; OSA, one-stage assay; SD, standard deviation.
a Results from one of the 51 assays were excluded due to a calculation error affecting all reported FVIII:C values.
b
Only 40 laboratories performed both assays; however, three of these performed more than one assay of a given type and all possible combinations were included in the analysis.
c Some values were excluded from the analysis because exact FVIII:C values were not provided; therefore, n is <43 (n = 36 for both 1 IU/dL samples and n = 40 for both 5 IU/dL samples). 
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